The U.S. Food and Drug Administration approved on Oct. 5 Boston Scientific’s Synergy bioabsorbable polymer drug-eluting stent, the first device of its kind to receive approval. The stent limits long-term polymer exposure by absorbing the abluminal bioabsorbable drug after three months when the drug elution is complete.

The approval is based on the results of the EVOLVE II trial, which found the stent to be non-inferior to a durable-polymer drug-eluting stent. 

Keywords: Drug-Eluting Stents, Polymers, Sirolimus, Stents, United States Food and Drug Administration, Coronary Artery Disease, Myocardial Infarction, Thrombosis

< Back to Listings